ESC Premium Access

Contemporary results from EHR study of real-world bleeding risk among elderly and overall non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban and warfarin

Congress Presentation

About the speaker

Mr Ruslan Horblyuk

New York (United States of America)
0 follower

8 more presentations in this session

Real world persistence, adherence and switch-over across anticoagulants in atrial fibrillation-a national population-based study.

Speaker: Doctor A. Banerjee (London, GB)


Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial

Speaker: Doctor M. Rao (Durham, US)


Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial

Speaker: Assistant Professor C. Melloni (Durham, US)


Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Speaker: Doctor O. Yin (Edison, New Jersey, US)


Direct oral anticoagulants in atrial fibrillation patients undergoing cardioversion. Nationwide multicentre study.

Speaker: Miss S. Itainen-Stromberg (Helsinki, FI)


Access the full session

New trends in antithrombotic therapy for atrial fibrillation

Speakers: Mr R. Horblyuk, Doctor A. Banerjee, Doctor M. Rao, Assistant Professor C. Melloni, Doctor O. Yin...

About the event



27 August - 31 August 2016

Sessions Presentations

Related content

Open Access

Welcome and introduction.

21 May 2022

EHRA Premium Access

Effectiveness and safety of edoxaban in 27,333 patients from ETNA-AF with and without a history of intracranial haemorrhage after 2 years of treatment

4 April 2022

ESC Premium Access

Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study

28 August 2021

ESC 365 is supported by

logo Novo Nordisk